Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to TradeZacks Investment Research • 12/08/23
What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/08/23
EyePoint announces $175 million stock offering following record surge in share priceMarket Watch • 12/04/23
EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatmentMarket Watch • 12/04/23
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary EndpointsGlobeNewsWire • 12/04/23
Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?Zacks Investment Research • 11/21/23
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call TranscriptSeeking Alpha • 11/01/23
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 11/01/23
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023GlobeNewsWire • 10/31/23
EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023GlobeNewsWire • 10/30/23
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023GlobeNewsWire • 10/25/23
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023GlobeNewsWire • 09/11/23
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/09/23
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/02/23